Surgery · 2025
Interleukin-22 and interleukin-22 binding protein signaling axis influences intubation status in trauma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Anderson Augustus E, Broome Jacob, Albuck Aaron L, Shenk Megan, Noguera Valeria, Covey Wid, Smith Alison, Duchesne Juan, Tatum Danielle, Bojanowski Christine M, Pociask Derek, Kolls Jay K, Jackson-Weaver Olan, Taghavi Sharven
Аннотация
BACKGROUND: Interleukin-22 is a cytokine involved in mucosal immunity, whereas interleukin-22 binding protein is a soluble receptor that can potently block interleukin-22. The role of interleukin-22 and interleukin-22 binding protein in trauma remains unclear. This study investigates whether IL-22 levels are associated with intubation in patients with trauma. We hypothesized interleukin-22 levels would be lower in intubated patients.
METHODS: Plasma samples were prospectively obtained in the trauma bay at consecutive Level 1 activations from November 2021 to November 2022. Patients were categorized as having respiratory failure (intubated) or as controls (nonintubated). Two-to-one case-control matching was conducted based on age, sex, mechanism of injury, and Injury Severity Score. Plasma interleukin-22 and interleukin-22 binding protein levels were measured by enzyme-linked immunosorbent assay.
RESULTS: In total, 99 patients were matched (33 respiratory failure and 66 controls), with a median age of 41 (interquartile range, 29-61). Interleukin-22 levels were lower in the respiratory failure group (32 pg/mL vs 39 pg/mL, P = .03). Lower interleukin-22 correlated with higher Injury Severity Score (r = -0.41, P < .001) and longer hospital stay (r = -0.26, P = .01). Multivariate analysis showed that lower interleukin-22 levels were independently associated with intubation (odds ratio, 0.97; 95% confidence interval, 0.95-0.99, P = .02).
CONCLUSION: Interleukin-22 may serve as a biomarker for trauma-induced respiratory failure, with lower levels associated with greater injury severity and the need for intubation. Further studies are needed to explore its potential as a therapeutic and to better understand its role in trauma care.
METHODS: Plasma samples were prospectively obtained in the trauma bay at consecutive Level 1 activations from November 2021 to November 2022. Patients were categorized as having respiratory failure (intubated) or as controls (nonintubated). Two-to-one case-control matching was conducted based on age, sex, mechanism of injury, and Injury Severity Score. Plasma interleukin-22 and interleukin-22 binding protein levels were measured by enzyme-linked immunosorbent assay.
RESULTS: In total, 99 patients were matched (33 respiratory failure and 66 controls), with a median age of 41 (interquartile range, 29-61). Interleukin-22 levels were lower in the respiratory failure group (32 pg/mL vs 39 pg/mL, P = .03). Lower interleukin-22 correlated with higher Injury Severity Score (r = -0.41, P < .001) and longer hospital stay (r = -0.26, P = .01). Multivariate analysis showed that lower interleukin-22 levels were independently associated with intubation (odds ratio, 0.97; 95% confidence interval, 0.95-0.99, P = .02).
CONCLUSION: Interleukin-22 may serve as a biomarker for trauma-induced respiratory failure, with lower levels associated with greater injury severity and the need for intubation. Further studies are needed to explore its potential as a therapeutic and to better understand its role in trauma care.